Ana Garcia-Blas

Valencia, VC 46010, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis.

The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis.

Journal: Biomolecules

Published: March 06, 2026

Differential adipose tissue remodeling and metabolic effects of dolutegravir and bictegravir: implications for HIV therapy.

Differential adipose tissue remodeling and metabolic effects of dolutegravir and bictegravir: implications for HIV therapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 04, 2025

Differential effects of antiretroviral HIV integrase inhibitors on vascular cell adhesion molecules.

Differential effects of antiretroviral HIV integrase inhibitors on vascular cell adhesion molecules.

Journal: Antiviral research

Published: June 26, 2025

Calorie restriction modulates mitochondrial dynamics and autophagy in leukocytes of patients with obesity.

Calorie restriction modulates mitochondrial dynamics and autophagy in leukocytes of patients with obesity.

Journal: Free radical biology & medicine

Published: August 27, 2024

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction.

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction.

Journal: Antiviral research

Published: August 09, 2024

Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH).

Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH).

Journal: Gastroenterologia y hepatologia

Published: April 15, 2024

Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD.

Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD.

Journal: Biomedicines

Published: April 12, 2024

Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation.

Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 15, 2024

Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease.

Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 18, 2023

Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress.

Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress.

Journal: Antioxidants (Basel, Switzerland)

Published: July 01, 2023

Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease.

Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease.

Journal: The Journal of pathology

Published: June 18, 2023

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets.

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets.

Journal: Frontiers in pharmacology

Published: October 17, 2022

Showing 1-12 of 56

Last Updated: 09/26/2026